Glytec, a leader in diabetes and insulin management software, has broadened its partnership with Roche, a prominent pharmaceutical company, to integrate its software with Roche’s cobas pulse, a point-of-care smart-device hospital blood glucose system. This expansion will facilitate the use of Glytec’s software in the U.S. and international markets, aiming to enhance patient safety, cost-efficiency, and overall care quality.
Roche highlights that the cobas pulse system delivers lab-quality results, significantly reducing the need for test repetition. Designed for use across all patient demographics, including newborns and those in intensive care, this system enhances accuracy and reliability in hospital settings.
Central to this partnership is Glytec’s Glucommander, an FDA-cleared insulin-dosing decision support software. Glucommander is instrumental in inpatient diabetes management, aiding healthcare providers in optimizing glycemic control and improving patient outcomes.
The collaboration is aligned with Glytec’s ongoing strategy to enhance diabetes and insulin management through synergistic efforts. By leveraging Roche’s extensive global reach and Glytec’s proven expertise, the partnership aims to set new benchmarks in patient safety, care cost-effectiveness, and outcome improvement.
“Diabetes is a global challenge that transcends borders, profoundly affecting hospital management and patient outcomes worldwide,” said Robby Booth, Glytec’s co-founder and chief strategy officer, in a statement. “Our expanded collaboration with Roche underscores our commitment to addressing this critical healthcare issue, benefiting patients, providers, and payers, and making a positive impact on lives around the world.”
Industry Context
This partnership is part of a broader trend in diabetes care innovation. In August, Glytec supported the Centers for Medicare & Medicaid Services’ (CMS) new mandatory reporting requirements aimed at enhancing hyperglycemia and hypoglycemia management. These efforts are particularly beneficial for rural and underserved communities, advancing value-based care initiatives across the United States.
Earlier this year, Glytec partnered with Major Health Partners (MHP), a community hospital in Shelbyville, Indiana. This collaboration introduced Glucommander to MHP’s insulin titration process, aiming to reduce severe hypoglycemia risks and standardize insulin management.
Additionally, in May, Glytec joined forces with the Cleveland Clinic to implement its insulin management platform at UH Cleveland Medical Center. The platform uses evidence-based algorithms and real-time data to customize insulin dosing for patients, enhancing care precision.
Glytec’s growth trajectory is supported by significant investments, including $21 million secured in 2021 from Silicon Valley Bank, Savitr Capital, and other private investors, with $9 million in debt financing and $12 million in equity investments.
The strengthened partnership with Roche marks another significant step in Glytec’s mission to transform diabetes management in hospitals globally, reflecting the company’s dedication to improving patient outcomes and healthcare efficiency.
Related topics:
Traveling With Diabetes in Cold Weather: Key Tips for Managing Your Health
Simple Blood Test Could Identify Cancer Risk in Type 2 Diabetes Patients, Study Suggests
